AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Update

Posted by Tyrone Williams on Aug 12th, 2024

AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totalling 11,600 shares, a decline of 78.2% from the July 15th total of 53,100 shares. Based on an average daily volume of 4,000 shares, the short-interest ratio is currently 2.9 days.

AstraZeneca Stock Performance

Shares of OTCMKTS AZNCF remained flat at $165.60 during trading hours on Monday. The company had a trading volume of 286 shares, compared to its average volume of 3,099. AstraZeneca has a 1-year low of $118.16 and a 1-year high of $165.60. The company’s 50 day moving average price is $157.00 and its 200-day moving average price is $144.68.

AstraZeneca Cuts Dividend

The business also recently declared a dividend, which will be paid on Monday, September 9th. Investors of record on Friday, August 9th will be given a $1.00 dividend. The ex-dividend date of this dividend is Wednesday, August 7th. AstraZeneca’s dividend payout ratio (DPR) is presently 343.14%.

Institutional Trading of AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Kennedy Capital Management LLC purchased a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.